[68Ga]Ga-FAPI-46 in Staging of Head and Neck Carcinomas

Official title

[68Ga]Ga-FAPI-46 PET/CT in Early Detection of Lymph Node Metastasis in Head and Neck Squamous Cell Carcinomas

Overview

The trial focuses on assessing the role of \[68Ga\]Ga-FAPI-46 in head and neck squamous cell carcinomas (HNSCC) staging before surgery. In the context of metastasis, cancer-associated fibroblasts (CAFs) emerge as pivotal contributors to the creation of a microenvironment conducive to future metastases. CAFs exert their influence through intricate mechanisms, including the remodeling of the extracellular matrix by secreting proteins such as collagen and fibronectin. This process enhances the structural support for cancer cell invasion into adjacent tissues. Additionally, CAFs play a central role in promoting angiogenesis, ensuring an adequate blood supply to the tumor, which may also facilitate the entry of cancer cells into the bloodstream. Through modulation of immune responses within the tumor microenvironment, CAFs establish an immunosuppressive milieu, providing a permissive environment for cancer cell survival and dissemination. Collectively, the orchestrated activities of CAFs contribute to the preparation of a metastatic niche, influencing the microenvironment at both primary and secondary sites and enhancing the likelihood of successful metastasis. Employing \[68Ga\]Ga-FAPI-46 PET/CT imaging to target activated CAFs may hold the potential to discern lymph nodes (LNs) predisposed to future metastases in HNSCC. The use of this imaging modality offers a unique opportunity to visualize and assess the presence and activity of CAFs within the tumor microenvironment. By targeting the fibroblast activation protein (FAP), a receptor enriched on CAFs, this imaging approach provides a specific and sensitive mean to identify regions where the microenvironment may favor metastatic progression. In this research endeavor, the primary objective is to highlight the additional value of \[68Ga\]Ga-FAPI-46 PET/CT into the standard pre-surgical imaging protocol. Additionally, the study will evaluate the efficacy of FAP positon emission tomography (PET) in primary tumor delineation. Imaging based on \[68Ga\]Ga-FAPI-46 allows the identification of CAFs, specifically by exploiting their increased FAP expression. The study aims also to systematically compare the \[68Ga\]Ga-FAPI-46 PET/CT signals with the characteristics of resected lymph nodes, seeking to ascertain the capability of FAPI PET imaging in identifying premetastatic conditions. By comparing the \[68Ga\]Ga-FAPI-46 PET signal and the histopathological features of resected lymph nodes, the goal is to validate the potential of \[68Ga\]Ga-FAPI-46 PET imaging as a tool for early detection of premalignant or metastatic conditions in the lymphatic system before surgical intervention. The ability to pinpoint lymph nodes at risk for future metastases could revolutionize clinical decision-making, by facilitating a more nuanced understanding of disease spread, thereby informing personalized treatment strategies and potentially improving patient outcomes.

Detailed description

\[68Ga\]Ga-FAPI-46 PET/CT is an advanced imaging technique utilized in nuclear medicine for the evaluation of various cancers. The imaging agent \[68Ga\]Ga-FAPI-46 specifically targets FAP, a protein overexpressed by CAFs in the tumor microenvironment. This targeted approach allows for precise visualization of FAP-positive tumors, aiding in the detection, staging, and assessment of therapeutic response. The integration of PET and CT modalities provides both functional and anatomical information, enhancing the accuracy of the imaging results. In this study, the investigators will specifically evaluate the application of \[68Ga\]Ga-FAPI-46 PET/CT in patients diagnosed with HNSCC who are scheduled for primary clinical resection. This research aims to explore the potential of \[68Ga\]Ga-FAPI-46 PET/CT in guiding treatment decisions and optimizing the management of HNSCC, contributing valuable insights to the growing knowledge in precision oncology.

Patients with confirmed HNSCC and planned to undergo tumor and LN dissection surgery will be recruited for this project. The included patients will follow their standard-of-care clinical investigations according to current guideline-based recommendations.

Patients will receive \[68Ga\]Ga-FAPI-46 in a dose of 2MBq/kg (+/-15%) as an IV injection. The total administered dose will be between 80 and 200MBq. 60 minutes (+/- 10min) after the injection, low-dose, non-contrast-enhanced PET/CT will be acquired for about 20 minutes.

Interventions

• Drug [68Ga]Ga-FAPI-46 PET/CT
  \[68Ga\]Ga-FAPI-46 PET/CT

Primary outcome measures

• [68Ga]Ga-FAPI-46 PET/CT imaging results: tumor size [Time frame: 6 weeks]
• [68Ga]Ga-FAPI-46 PET/CT imaging results: tumor volume [Time frame: 6 weeks]
• [68Ga]Ga-FAPI-46 PET/CT imaging results: tumor SUVmax [Time frame: 6 weeks]
• [68Ga]Ga-FAPI-46 PET/CT imaging results: number of lesions [Time frame: 6 weeks]
• [68Ga]Ga-FAPI-46 PET/CT imaging results: lesion site [Time frame: 6 weeks]
• [68Ga]Ga-FAPI-46 PET/CT imaging results: lesion size [Time frame: 6 weeks]
• [68Ga]Ga-FAPI-46 PET/CT imaging results: lesion volume [Time frame: 6 weeks]
• [68Ga]Ga-FAPI-46 PET/CT imaging results: lesion SUVmax [Time frame: 6 weeks]
• [68Ga]Ga-FAPI-46 PET/CT imaging results: TNM tumor stage [Time frame: 6 weeks]

Secondary outcome measures (1)

• Ability of [68Ga]Ga-FAPI-46 PET/CT to visualize tumor infiltration in lymph nodes [Time frame: 2 months]

Eligibility criteria

Inclusion criteria

• Age ≥18 years old
• Karnofsky index ≥80%
• Patients with operable head and neck cancer presenting histologically proven HNSCC (including Oral Cavity Cancer, Pharyngeal Cancer, Laryngeal Cancer)
• Patients with at least one nodal metastasis
• Patients scheduled for neck dissection
• SOC imaging (MRI, ceCT and 18F-FDG-PET/CT) performed as pre-surgery exams
• Written informed consent obtained

Exclusion criteria

• Known pregnancy or ongoing breast feeding
• Claustrophobia
• Severe renal insufficiency (GFR<30 mL/min/1,73 m2)
• Liver enzymes (ALAT, ASAT)>5 times the standard upper limit
• Bilirubin>3 times the standard upper limit
• Hemoglobin<8 g/dL
• Absolute neutrophil count<1000/mm3
• Platelets<75000/µL
• insufficient knowledge of project language, inability to give consent or to follow trial-associated procedures
• the patient makes use of his/her "right not to know" and refuses to be informed about incidental findings

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

N/A

Model

Single group

Masking

Open label

Primary purpose

Diagnostic

Study locations

Switzerland · 1 center

• Centre hospitalier universitaire vaudois — Lausanne

Identifiers

NCT: NCT06794372 · FAPIHN · 2024-01881

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗